50,799 Shares in InMode Ltd. (NASDAQ:INMD) Acquired by Atlas Legacy Advisors LLC

Atlas Legacy Advisors LLC acquired a new position in InMode Ltd. (NASDAQ:INMD) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 50,799 shares of the healthcare company’s stock, valued at approximately $848,000. Atlas Legacy Advisors LLC owned about 0.06% of InMode at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in INMD. Nisa Investment Advisors LLC boosted its holdings in shares of InMode by 314.7% in the third quarter. Nisa Investment Advisors LLC now owns 3,550 shares of the healthcare company’s stock worth $60,000 after buying an additional 2,694 shares during the last quarter. GW Henssler & Associates Ltd. purchased a new position in shares of InMode in the third quarter worth approximately $177,000. EMC Capital Management boosted its holdings in shares of InMode by 219.4% in the third quarter. EMC Capital Management now owns 13,319 shares of the healthcare company’s stock worth $226,000 after buying an additional 9,149 shares during the last quarter. Harvey Capital Management Inc. boosted its holdings in shares of InMode by 57.1% in the third quarter. Harvey Capital Management Inc. now owns 50,790 shares of the healthcare company’s stock worth $861,000 after buying an additional 18,450 shares during the last quarter. Finally, Easterly Investment Partners LLC raised its stake in InMode by 26.6% during the 3rd quarter. Easterly Investment Partners LLC now owns 121,589 shares of the healthcare company’s stock worth $2,061,000 after acquiring an additional 25,579 shares during the period. Hedge funds and other institutional investors own 68.04% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Needham & Company LLC restated a “hold” rating on shares of InMode in a research note on Tuesday, February 4th. Barclays raised their target price on shares of InMode from $26.00 to $29.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 5th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $22.25.

InMode Price Performance

InMode stock opened at $19.11 on Wednesday. The stock has a market cap of $1.33 billion, a P/E ratio of 8.13 and a beta of 2.13. InMode Ltd. has a 1 year low of $14.87 and a 1 year high of $23.46. The firm’s 50 day moving average price is $17.35 and its 200-day moving average price is $17.25.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.